Reports

Drug name	NICE TAs	Comments
Temozolomide capsules	TA121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma TA23 - Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temsirolimus infusion (Torisel®)	TA207 - Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (Negative TA) TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA)	Hospital use only
Tenecteplase	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction TA990 - Tenecteplase for treating acuse ischaemic stroke	Hospital use only
Teriflunomide	TA303 - Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide injection	TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Tezepelumab	TA880 - Tezepelumab for treating severe asthma
Thalidomide capsules	TA228 - Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Ticagrelor tablets	TA236 - Ticagrelor for the treatment of acute coronary syndromes
Tildrakizumab	TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis
Timodine cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild steroid potency

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports